StreetInsider.com News Articles

AIAI Deploys Bid Accelerator, Showcasing Its Transformational AI Integration Strategy

Wed, 22 Jul 2026 08:30:00 -0400

Purpose-built AI application deployed at C.C. Carlton Industries, demonstrating AIAI's Transformational AI strategy from framework to operational execution

DALLAS, TX / ACCESS Newswire / July 22, 2026 / AIAI Holdings Corporation (NASDAQ:AIAI) ("Ai²" or the "Company"), an AI-enabled diversified holding company utilizing Transformational AI (TAI) to enhance portfolio performance, today announced the deployment of Bid Accelerator a custom built application developed under the Company's Transformational AI (TAI) Integration Playbook, which was introduced in June to provide a disciplined framework for identifying, designing and implementing AI-enabled value creation opportunities across its

AIAI Deploys Bid Accelerator, Showcasing Its Transformational AI Integration Strategy

Wed, 22 Jul 2026 08:30:00 -0400

Purpose-built AI application deployed at C.C. Carlton Industries, demonstrating AIAI's Transformational AI strategy from framework to operational execution

MediGuide launches AI-assisted precision healthcare platform

Tue, 14 Jul 2026 10:43:06 -0400

AIAI Holdings Corporation (NASDAQ: AIAI) announced that its portfolio company MediGuide has launched a precision healthcare solution that combines genetic, molecular, and clinical data with AI-enabled analytics and physician review.

The new offering builds on MediGuide's existing Medical Second Opinion services. Key capabilities include comprehensive diagnostics integrating genetic and molecular information, AI-assisted clinical insights, personalized treatment guidance, and tools aimed at earlier detection of health risks.

"Every patient is different, yet too many healthcare decisions are still guided by generalized treatment approaches," said Vera Guerreiro, Chief Executive Officer of MediGuide. "Our precision healthcare solution brings together advanced medical intelligence, expert clinical review,

AIAI Holdings' MediGuide Enters the State-of-the-Art Medicine Market With AI-Driven Innovation

Tue, 14 Jul 2026 10:40:00 -0400

Leveraging Advanced Diagnostics and Screenings to Provide Personalized Proactive Care

DALLAS, TX / ACCESS Newswire / July 14, 2026 / AIAI Holdings Corporation (NASDAQ:AIAI) ("Ai²" or the "Company"), an AI-enabled diversified holding company utilizing Transformational AI (TAI) to enhance portfolio performance, today announced that its portfolio company, MediGuide, has launched a state of the art (SOTA) precision healthcare solution that combines advanced medical intelligence, expert clinical review, and AI-enabled diagnostic support to enable more personalized, data-driven medical decision-making.

The launch represents another milestone in MediGuide's innovation roadmap and reflects AIAI Holdings'

AIAI Holdings' MediGuide Enters the State-of-the-Art Medicine Market With AI-Driven Innovation

Tue, 14 Jul 2026 10:40:00 -0400

Leveraging Advanced Diagnostics and Screenings to Provide Personalized Proactive Care

The launch represents another milestone in MediGuide's innovation roadmap and reflects AIAI Holdings'

NetraMark Engages AM Public Relations to Support Strategic Communications and Market Awareness

Mon, 13 Jul 2026 07:00:00 -0400

TORONTO, July 13, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the "Company" or "NetraMark") (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), an artificial intelligence company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, today announced it has engaged AM Public Relations (AM PR), a healthcare-focused public relations agency specializing in media relations, thought leadership, and strategic communications for healthcare and technology companies.

The engagement is intended to support NetraMark's broader communications strategy as the Company continues to advance its proprietary NetraAI platform and expand industry

NetraMark Engages AM Public Relations to Support Strategic Communications and Market Awareness

Mon, 13 Jul 2026 07:00:00 -0400

The engagement is intended to support NetraMark's broader communications strategy as the Company continues to advance its proprietary NetraAI platform and expand industry

NetraMark Engages AM Public Relations to Support Strategic Communications and Market Awareness

Mon, 13 Jul 2026 07:00:00 -0400

The engagement is intended to support NetraMark's broader communications strategy as the Company continues to advance its proprietary NetraAI platform and expand industry

NetraMark Engages AM Public Relations to Support Strategic Communications and Market Awareness

Mon, 13 Jul 2026 07:00:00 -0400

The engagement is intended to support NetraMark's broader communications strategy as the Company continues to advance its proprietary NetraAI platform and expand industry

NetraMark Engages AM Public Relations to Support Strategic Communications and Market Awareness

Mon, 13 Jul 2026 07:00:00 -0400

The engagement is intended to support NetraMark's broader communications strategy as the Company continues to advance its proprietary NetraAI platform and expand industry

NetraMark Engages AM Public Relations to Support Strategic Communications and Market Awareness

Mon, 13 Jul 2026 07:00:00 -0400

The engagement is intended to support NetraMark's broader communications strategy as the Company continues to advance its proprietary NetraAI platform and expand industry

NetraMark Engages AM Public Relations to Support Strategic Communications and Market Awareness

Mon, 13 Jul 2026 07:00:00 -0400

The engagement is intended to support NetraMark's broader communications strategy as the Company continues to advance its proprietary NetraAI platform and expand industry

NetraMark Engages AM Public Relations to Support Strategic Communications and Market Awareness

Mon, 13 Jul 2026 07:00:00 -0400

The engagement is intended to support NetraMark's broader communications strategy as the Company continues to advance its proprietary NetraAI platform and expand industry

NetraMark signs first CRO contract to analyze neurodegeneration data

Thu, 09 Jul 2026 07:00:22 -0400

NetraMark Holdings Inc. (TSX: AIAI) (OTCQB: AINMF) signed a contract to analyze phase 2 neurodegeneration clinical trial data through a contract research organization (CRO) partner, the Toronto-based company announced July 9, 2026.

The agreement marks the company's first contract flowing through a CRO rather than directly with a biopharmaceutical company. Under the deal, NetraMark will apply its NetraAI platform to identify what it calls Model-Derived Subgroups and treatment-response patterns within the neurodegenerative disease dataset.

"This contract is an important commercial milestone for NetraMark because it represents our first contract flowing through a CRO, rather than directly with a biopharmaceutical company," said George

NetraMark signs first CRO contract to analyze neurodegeneration data

Thu, 09 Jul 2026 07:00:22 -0400

"This contract is an important commercial milestone for NetraMark because it represents our first contract flowing through a CRO, rather than directly with a biopharmaceutical company," said George

NetraMark signs first CRO contract to analyze neurodegeneration data

Thu, 09 Jul 2026 07:00:22 -0400

"This contract is an important commercial milestone for NetraMark because it represents our first contract flowing through a CRO, rather than directly with a biopharmaceutical company," said George

NetraMark signs first CRO contract to analyze neurodegeneration data

Thu, 09 Jul 2026 07:00:22 -0400

"This contract is an important commercial milestone for NetraMark because it represents our first contract flowing through a CRO, rather than directly with a biopharmaceutical company," said George

NetraMark Signs New Contract To Analyze Phase 2 Neurodegeneration Trial Data With Contract Research Organization Partner